Collaboration and the Cure for Cancer with speakers David Agus and Larry Norton speaking at the 2007 Aspen Ideas Festival. Robin Portman moderates.
In this, its third year, Aspen Ideas Festival once again gathers scientists, artists, politicians, historians, educators, activists, and other great thinkers around some of the most important and fascinating ideas of our time. As these thinkers present their provocative ideas, they engage a sophisticated and highly motivated audience.
Dr. David B. Agus
David Agus is one of the world’s top cancer doctors and a pioneer in new technologies for personalized health care. A professor at USC, with appointments in both the Keck School of Medicine and the Viterbi School of Engineering, he also heads the university’s Westside Cancer Center and the Center for Applied Molecular Medicine. He has cofounded several businesses, including the genetic testing company Navigenics and Oncology.com. He is also a cofounder of Applied Proteomics, which aims to tap the tremendous wealth of information contained in the body’s proteome—the complete set of all proteins circulating in the bloodstream—for earlier diagnosis of disease. Agus is a CBS News contributor and author of the number one New York Times best seller The End of Illness. His new book, A Short Guide to a Long Life, will be published in January 2014.
Larry Norton, MD, is deputy physician-in-chief for breast cancer programs at Memorial Sloan-Kettering Cancer Center and medical director of Memorial Sloan-Kettering 64th Street, comprised of the Evelyn H. Lauder Breast Center and the Iris Cantor Diagnostic Center. His research concerns the basic biology of cancer, the mathematics of tumor causation and growth, and developing approaches to better diagnosis, prevention, and drug treatment of the disease. He has also developed a new approach to therapy that uses anticancer drugs based on a mathematical model maximizing the killing of cancer cells while minimizing toxicity. The principal investigator of a grant from the National Cancer Institute to better understand breast cancer in the laboratory and to bring these advances into clinical practice, he has also served on the NCIâ€™s board of directors.
Robin Portman is a vice president at Booz Allen Hamilton. Portman has more than 15 years of strategy development and technology delivery experience. She leads consulting and technology delivery engagements for the firmâ€™s Global Health business, focusing on clients for both the US federal and commercial health industry including the Department of Health and Human Services, the National Institutes of Health, the Department of Veterans Affairs, and the US Military Health System. Under her leadership, Booz Allen provides technology management, development, and integration for health and research domains, including clinical data management, clinical trials and research study support, collaborative science, biomedical informatics, and electronic health records systems. Portman has published on her breakthrough work in collaborative science in the firmâ€™s quarterly business journal, strategy+business magazine.